SALT LAKE CITY, June 2, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today presented several clinical studies on the Myriad myRisk™ Hereditary Cancer test at the 2014 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Illinois. Among the important new findings is that the myRisk test detects significantly more deleterious mutations than single cancer tests and helps solve the overlap dilemma that exists among hereditary cancer syndromes.
Help employers find you! Check out all the jobs and post your resume.
